Expect pricing and availability to continue shifting into 2026
Observational data from weight loss clinics report that approximately 6070% of patients who plateau on semaglutide experience renewed weight loss after transitioning to tirzepatide, often with continued improvements over 1224 weeks
Primary Meta-Analysis Across 10 RCTs (n= 366 ALC
Stock your fridge and pantry with healthy, filling snacks to avoid impulsive eating
Secondary, safety and negative control endpoints For individual components of the primary endpoint, semaglutide versus sitagliptin reduced myocardial infarction (HR 0.81, 95% CI 0.70 to 0.92) and stroke (HR 0.84, 95% CI 0.71 to 0.99) in the expanded populations at low, moderate and high cardiovascular risk
A medical professional can evaluate individual health situations, discuss potential risks and benefits, and advise on established, evidence-based treatments